Trabecular and cortical bone involvement in rheumatoid arthritis by DXA and DXA-based 3D modelling.

Rheumatoid arthritis (RA) patients had a higher risk of developing low bone mineral density (BMD) or osteoporosis. RA patients on classic disease-modifying antirheumatic drug (c-DMARD) therapy showed significantly lower BMD than controls, while no significant differences in most parameters were found between RA patients receiving biological disease-modifying antirheumatic drugs (b-DMARDs) and controls. The 3D analysis allowed us to find changes in the trabecular and cortical compartments. INTRODUCTION: To evaluate cortical and trabecular bone involvement of the hip in RA patients by dual-energy X-ray absorptiometry (DXA) and 3D analysis. The secondary end-point was to evaluate bone involvement in patients treated with classic (c-DMARD) or biological (b-DMARD) disease-modifying antirheumatic drug therapies and the effect of the duration of the disease and corticosteroid therapy on 3D parameters. METHODS: A cross-sectional study of 105 RA patients and 100 subjects as a control group (CG) matched by age, sex, and BMI was carried out. BMD was measured by DXA of the bilateral femoral neck (FN) and total hip (TH). The 3D analyses including trabecular and cortical BMD were performed on hip scans with the 3D-Shaper software. RESULTS: FN and TH BMD and trabecular and cortical vBMD were significantly lower in RA patients. The c-DMARD (n = 75) group showed significantly lower trabecular and cortical vBMD than the CG. Despite the lower values, the b-DMARD group (n = 30) showed no significant differences in most parameters compared with the CG. The trabecular and cortical 3D parameters were significantly lower in the group with an RA disease duration of 1 to 5 years than in the CG, and the trabecular vBMD was significantly lower in the group with a duration of corticosteroid therapy of 1 to 5 years than in the CG, while no significant differences were found by standard DXA in the same period. CONCLUSIONS: RA patients had a higher risk of developing low BMD or osteoporosis than controls. RA patients receiving c-DMARD therapy showed significantly lower BMD than controls, while no significant differences in most parameters were found between RA patients receiving b-DMARDs and controls. 3D-DXA allowed us to find changes in trabecular and cortical bone compartments in RA patients.

Validation of the Spanish, Portuguese and French versions of the Lupus Damage Index questionnaire: data from North and South America, Spain and Portugal.

We have previously developed and validated a self-administered questionnaire, modelled after the Systemic Lupus International Collaborating Clinics Damage Index (SDI), the Lupus Damage Index Questionnaire (LDIQ), which may allow the ascertainment of this construct in systemic lupus erythematosus (SLE) patients followed in the community and thus expand observations made about damage. We have now translated, back-translated and adapted the LDIQ to Spanish, Portuguese and French and applied it to patients followed at academic and non-academic centres in North and South America, Portugal and Spain while their physicians scored the SDI. A total of 887 patients (659 Spanish-speaking, 140 Portuguese-speaking and 80 French-speaking patients) and 40 physicians participated. Overall, patients scored all LDIQ versions higher than their physicians (total score and all domains). Infrequent manifestations had less optimal clinimetric properties but overall agreement was more than 95% for the majority of items. Higher correlations were observed among the Spanish-speaking patients than the Portuguese-speaking and French-speaking patients; further adjustments may be needed before the Portuguese and French versions of the LDIQ are applied in community-based studies. The relationship between the LDIQ and other outcome parameters is currently being investigated in a different patient sample.

Amerindian ancestry in Argentina is associated with increased risk for systemic lupus erythematosus.

Previous studies have demonstrated that in admixed populations, West African ancestry is associated with an increased prevalence of systemic lupus erythematosus (SLE). In the current study, the effect of Amerindian ancestry in SLE was examined in an admixed population in Argentina. The Argentine population is predominantly European with approximately 20% Amerindian admixture, and a very small (<2%) contribution from West Africa. The results indicate that Amerindian admixture in this population is associated with a substantial increase in SLE susceptibility risk (Odds Ratio=7.94, P=0.00006). This difference was not due to known demographic factors, including site of collection, age and gender. In addition, there were trends towards significance for Amerindian ancestry influencing renal disease, age of onset and anti-SSA antibodies. These studies suggest that populations with Amerindian admixture, like those with West African admixture, should be considered in future studies to identify additional allelic variants that predispose to SLE.

[Antipyretic effect of indomethacin vs aspirin in fever of tumor origin]. / Efecto antipirético de la indometacina versus aspirina en la fiebre de origen tumoral.

Fever is frequently a symptom in patients suffering from cancer and in most cases it is related to infections or complications of the treatment. Some cancers can also be the direct cause of fever. A total of 28 episodes of fever in 8 patients with cancer were studied. The diagnoses were: 3 patients with lung cancer, 1 patient with chronic myelogenous leukemia, 1 patient with kidney cancer, 2 patients with non-Hodgkin lymphoma, and 1 patient with Hodgkin's disease. Were included cancer diagnosed patients of any age and sex, with three or more episodes of fever of more than 37.5 C (with a case of 38.5 C or more) after having eliminated any infectious etiology or fever caused by drugs. Were not excluded any patients who had received whole blood or blood derivative transfusions, chemotherapy or antibiotic treatment up to 48 hs before the fever peak. The patients were given intramuscularly 500 mg of aspirin or 50 mg of indomethacin. The first response in the temperature curve was evaluated while checking the axillary temperature six hours after drug administration and 48 hs later if the fever persisted. The patients who were given aspirin at first, were then given indomethacin and vice versa, using the same criteria to evaluate the response. In patients treated with indomethacin the temperature diminished quickly and completely (Fig. 1), unlike the effect achieved with the use of aspirin (Fig. 2). All patients treated with indomethacin also showed a remarkable clinical improvement which was not observed when aspirin was used.(ABSTRACT TRUNCATED AT 250 WORDS)

Sexto reporte de eventos adversos con tratamientos biológicos en Argentina: Informe del registro BIOBADASAR / Sixth report of adverse events with biological treatments in Argentina: Report of the BIOBADASAR registry

Objetivo: Actualizar los resultados del registro BIOBADASAR sobre seguridad, duración y causas de interrupción del tratamiento luego de 8 años de seguimiento. Métodos: BIOBADASAR es un registro de seguridad de terapias biológicas establecido por la Sociedad Argentina de Reumatología. Se presenta la descripción de BIOBADASAR 3.0, una cohorte compuesta por 53 centros de Argentina seguidos prospectivamente desde agosto de 2010 hasta enero de 2018. Resultados: Se registraron 4656 pacientes, 6234 tratamientos [3765 casos (terapia con biológicos) y 2469 controles (terapia no biológicos)]. Se interrumpió el tratamiento en el 44,6% en los casos vs. 27,9% en los controles. Causa principal de discontinuación fue por ineficacia (40% casos vs. 32% controles). Se presentaron 3154 eventos adversos (2230 en casos vs. 924 en controles), de los cuales el 13,6% fueron graves (9,8% en casos y 3,7% en controles). El evento adverso (EA) más frecuente en ambos grupos fueron las infecciones (43,56% en casos vs. 34,31% en los controles, RR: 3,42; IC 95%: 3,02-3,88), y de ellas las de vías aéreas superiores (14,5%). Las neoplasias se presentaron en 78 casos vs. 45 en controles (RR: 1,98; IC 95%: 1,37-2,86). Conclusiones: En este sexto reporte no se observan tendencias diferentes sobre seguridad, duración y causas de interrupción del tratamiento respecto a informes previos. Las infecciones fueron el principal EA y la ineficacia, seguido por EA y la pérdida de pacientes las principales causas de suspensión del tratamiento. El advenimiento de nuevos agentes biológicos y la necesidad de control en seguridad a largo plazo, fortalece el uso de este tipo de registro.

Objective: Update the results of the BIOBADASAR registry on safety, duration and causes of treatment interruption after 8 years of follow-up. Methods: BIOBADASAR is a safety record of biological therapies established by the Argentine Society of Rheumatology. The description of BIOBADASAR 3.0 is presented, a cohort of 53 centers in Argentina followed prospectively from August 2010 to January 2018. Results: 4656 patients were registered, 6234 treatments [3765 cases (therapy with biologicals) and 2469 controls (non-biological therapy)]. Treatment was interrupted in 44.6% in cases vs. 27.9% in controls. Main cause of discontinuation was due to inefficiency (40% cases vs. 32% controls). There were 3154 adverse events (2230 in cases vs. 924 in controls), of which 13.6% were tombs (9.8% in cases and 3.7% in controls). The most frequent adverse event (AE) in both groups were infections (43.56% in cases vs. 34.31% in controls, RR: 3.42, 95% CI: 3.02-3.88), and the upper airway pathways (14.5%). Neoplasms were published in 78 cases versus 45 controls (RR: 1.98, 95% CI: 1.37-2.86). Conclusions: In this article, there are no different trends regarding safety, duration and causes of interruption of treatment compared to previous reports. Infections were the main causes of treatment discontinuation. The advent of new biological agents and the need for control over long-term security, strengthens the use of this type of registration.

No evidence of association between genetic variants of the PDCD1 ligands and SLE.

PDCD1, an immunoreceptor involved in peripheral tolerance has previously been shown to be genetically associated with systemic lupus erythematosus (SLE). PDCD1 has two ligands whose genes are located in close proximity on chromosome 9p24. Our attention was drawn to these ligands after finding suggestive linkage to a marker (gata62f03, Z=2.27) located close to their genes in a genome scan of Icelandic families multiplex for SLE. Here, we analyse Swedish trios (N=149) for 23 single nucleotide polymorphisms (SNPs) within the genes of the PDCD1 ligands. Initially, indication of association to eight SNPs was observed, and these SNPs were therefore also analysed in Mexican trios (N=90), as well as independent sets of patients and controls from Sweden (152 patients, 448 controls) and Argentina (288 patients, 288 controls). We do not find support for genetic association to SLE. This is the first genetic study of SLE and the PDCD1 ligands and the lack of association in several cohorts implies that these genes are not major risk factors for SLE.

Efecto antipirético de la indometacina versus aspirina en la fiebre de origen tumoral / Antipyretic effect of indomethacin vs aspirin in fever of tumor origin

La fiebre se presenta frecuentemente como síntoma en pacientes con cáncer y en la mayoría de los casos está relacionada con complicaciones infecciosas o intervenciones terapéuticas. Algunos cánceres son capaces de producir fiebre por sí mismos. Se tomaron 28 epidódios febriles en 8 pacientes con cáncer internados en nuestro Servicio. Se concluyeron pacientes febriles con diagnóstico de cáncer de cualquier edad y sexo, en los cuales se descartó la etiología infecciosa y a la fiebre por drogas. Se administraron al azar 500 mg de aspirina o 50 mg de indometacina por vía intramuscular, y la respuesta fue evaluada en forma horaria durante las primeras 6 hs. En los pacientes tratados con indometacina se produjo una respuesta inicial completa y permanecieron afebriles hasta 48 hs después. En los pacients tratados con aspirina no se logró el control de la fiebre. Los resultados obtenidos demuestran que al indometacina a las dosis y vía propuestas, fue significativamente superior a la aspirina en el control de los episodios febriles (p < 0,01), y de acuerdo con estos resultados, la indometacina podría ser de utilidad en el tratamiento sintomático de la fiebre de origen tumoral

Efecto antipirético de la indometacina versus aspirina en la fiebre de origen tumoral. / [Antipyretic effect of indomethacin vs aspirin in fever of tumor origin]

Fever is frequently a symptom in patients suffering from cancer and in most cases it is related to infections or complications of the treatment. Some cancers can also be the direct cause of fever. A total of 28 episodes of fever in 8 patients with cancer were studied. The diagnoses were: 3 patients with lung cancer, 1 patient with chronic myelogenous leukemia, 1 patient with kidney cancer, 2 patients with non-Hodgkin lymphoma, and 1 patient with Hodgkins disease. Were included cancer diagnosed patients of any age and sex, with three or more episodes of fever of more than 37.5 C (with a case of 38.5 C or more) after having eliminated any infectious etiology or fever caused by drugs. Were not excluded any patients who had received whole blood or blood derivative transfusions, chemotherapy or antibiotic treatment up to 48 hs before the fever peak. The patients were given intramuscularly 500 mg of aspirin or 50 mg of indomethacin. The first response in the temperature curve was evaluated while checking the axillary temperature six hours after drug administration and 48 hs later if the fever persisted. The patients who were given aspirin at first, were then given indomethacin and vice versa, using the same criteria to evaluate the response. In patients treated with indomethacin the temperature diminished quickly and completely (Fig. 1), unlike the effect achieved with the use of aspirin (Fig. 2). All patients treated with indomethacin also showed a remarkable clinical improvement which was not observed when aspirin was used.(ABSTRACT TRUNCATED AT 250 WORDS)

Efecto antipirético de la indometacina versus aspirina en la fiebre de origen tumoral / Antipyretic effect of indomethacin vs aspirin in fever of tumor origin

La fiebre se presenta frecuentemente como síntoma en pacientes con cáncer y en la mayoría de los casos está relacionada con complicaciones infecciosas o intervenciones terapéuticas. Algunos cánceres son capaces de producir fiebre por sí mismos. Se tomaron 28 epidódios febriles en 8 pacientes con cáncer internados en nuestro Servicio. Se concluyeron pacientes febriles con diagnóstico de cáncer de cualquier edad y sexo, en los cuales se descartó la etiología infecciosa y a la fiebre por drogas. Se administraron al azar 500 mg de aspirina o 50 mg de indometacina por vía intramuscular, y la respuesta fue evaluada en forma horaria durante las primeras 6 hs. En los pacientes tratados con indometacina se produjo una respuesta inicial completa y permanecieron afebriles hasta 48 hs después. En los pacients tratados con aspirina no se logró el control de la fiebre. Los resultados obtenidos demuestran que al indometacina a las dosis y vía propuestas, fue significativamente superior a la aspirina en el control de los episodios febriles (p < 0,01), y de acuerdo con estos resultados, la indometacina podría ser de utilidad en el tratamiento sintomático de la fiebre de origen tumoral (AU)